Biochemistry & Pharmacology: Open Access
Open Access
ISSN: 2167-0501
+44-20-4587-4809
ISSN: 2167-0501
+44-20-4587-4809
Yanhong Gu
The First Affiliated Hospital with Nanjing Medical University,
300 Guangzhou Road, Nanjing 210029
China
Research Article
Iguratimod Synergizes with Methotrexate to Exert Anti-Inflammatory and Bone-Protective Effect and Block the Progression of Collagen-Induced Arthritis in Mices
Author(s): Qiong Luo, Yang Sun, Biao Jin, Wei Zheng, Fenli Shao, Nan Hang, Yongqian Shu, Xiaomin Li, Yanhong Gu and Qiang XuQiong Luo, Yang Sun, Biao Jin, Wei Zheng, Fenli Shao, Nan Hang, Yongqian Shu, Xiaomin Li, Yanhong Gu and Qiang Xu
Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic synovial inflammation and disability.
The most widely used Disease-Modifying Antirheumatic Drug (DMARD) is methotrexate and it continues to be the gold
standard. However, the use of high-dose methotrexate is associated with severe adverse effects. Iguratimod, which is
currently used in clinics in China and Japan, is a novel oral DMARD for the treatment of RA. In this study, the effect
of combination of methotrexate and iguratimod on murine Collagen-Induced Arthritis (CIA) and its mechanism was
determined. Oral administration of iguratimod (3 mg/kg, 10 mg/kg) combined with methotrexate (1 mg/kg) potently
blocked CIA development and delayed its progression, which was stronger than iguratimod or methotrexate used alone.
Furthermore, infiltration of inflammatory cel.. View More»
DOI:
10.4172/2167-0501.1000135